[144] Arcutis Biotherapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Insider sale notice for Arcutis Biotherapeutics, Inc. (ARQT). The filer reports a proposed sale of 10,000 common shares via Merrill (Columbus, OH) with an aggregate market value of $156,083 and an approximate sale date of 09/02/2025 on NASDAQ. The shares were acquired by stock option exercise on 03/13/2019 and payment is listed as cash. The filing also discloses three sales by Howard Welgus totaling 29,347 shares during June–August 2025, generating gross proceeds of $405,406 combined. The notice includes the standard representation that the seller has no undisclosed material adverse information.

Positive

• Disclosure compliance: The filer provided required Rule 144 details including acquisition date, method, and proposed sale date
• Transparency of recent activity: Past three months' sales by the insider are fully disclosed with gross proceeds

Negative

• No trading-plan date provided: The filing does not state a 10b5-1 plan adoption date or explanation for sales, leaving intent unclear

Insights

Securities Analyst

TL;DR: This Form 144 reports routine insider selling of vested option shares; disclosed past sales are sizable but not necessarily material to valuation.

The filing shows a proposed sale of 10,000 common shares acquired through option exercise in 2019 and sold for cash, with prior sales by the same insider of 29,347 shares in the past three months generating $405,406. For investors, this is a disclosure of insider liquidity rather than operational performance. Absent additional context on insider ownership percentage or reasons for sale, the transaction is informational and typically categorized as non-material to the company’s fundamentals.

Corporate Governance Expert

TL;DR: The filing documents a compliance filing for Rule 144 sales; it meets procedural disclosure requirements.

The notice indicates the seller affirms no undisclosed material adverse information and references potential reliance on a trading plan or 10b5-1 instructions though no plan date is provided. From a governance perspective, timely Rule 144 notices and the inclusion of recent sale history support regulatory transparency. Lack of additional explanatory remarks or a stated trading-plan adoption date leaves the governance context incomplete.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill 8890 Lyra Dr 5th Flr Columbus OH 43240	10000	156083.00	119905078	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/13/2019	Stock Option Exercise	Arcutis Biotherapeutics Inc			10000	09/02/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Howard Welgus 3027 Townsgate rd Suite 300 Westlake Village CA 91361	Common	07/01/2025	9208	127155.00
Howard Welgus 3027 Townsgate rd, Suite 300 Westlake Village CA 91361	Common	08/01/2025	10000	142982.00
Howard Welgus 3027 Townsgate rd, Suite 300 Westlake Village CA 91361	Common	06/18/2025	10139	135269.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Form 144 filed by ARQT disclose?

The filing discloses a proposed sale of 10,000 common shares worth $156,083 with an approximate sale date of 09/02/2025 and prior insider sales totaling 29,347 shares in June–August 2025.

How were the 10,000 ARQT shares acquired?

The shares were acquired by stock option exercise on 03/13/2019, and the planned sale consideration is listed as cash.

Which broker is handling the proposed sale?

The proposed sale lists Merrill (8890 Lyra Dr, Columbus, OH) as the broker.

How much did the insider receive from recent ARQT sales?

Three disclosed sales in the past three months generated gross proceeds of $127,155, $142,982, and $135,269, totaling $405,406.

Does the filing indicate undisclosed material information?

The signer represents they do not know any material adverse information that has not been publicly disclosed.